Fig. 4
From: Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Kaplan–Meier curves of progression free survival of patients treated with crizotinib and ceritinib according to the ALK fusion variants. a EML4 (N = 20) versus non-EML4 (N = 12) on crizotinib. b Demonstration of progression free survival of each variant (v1, N = 10; v2, N = 2; v3a/b, N = 8; non-EML4, N = 12) on crizotinib. c EML4 (N = 9) versus non-EML4 (N = 5) on ceritinib. d Demonstration of progression free survival of each variant (v1, N = 5; v2, N = 1; v3a/b, N = 3; non-EML4, N = 5) on ceritinib. Each symbol on the plot marks a censored patient. v1, EML4-ALK variant 1; v2, EML4-ALK variant 2; v3a/b, EML4-ALK variant 3a/b